ClinicalTrials.gg
CompletedNCT06501573Updated Sep 4, 2026

A Study of SGB-9768 in Adult Healthy Volunteers

A Phase 1 interventional study of SGB-9768 and Placebo in Healthy Volunteer, sponsored by Suzhou Sanegene Bio Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Suzhou Sanegene Bio Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.

Read the detailed description

It is a phase 1, randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768. The primary objective is to evaluate the safety, tolerability of SGB-9768 when administered subcutaneously as a single dose to healthy volunteers. The secondary objective is to characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Suzhou Sanegene Bio Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 55 years are included at the time of .
  • between 18 and 28 kg/m2 at screening, inclusive, at screening a weight of at least 45 kg for female and 50 kg for male.
  • Physical examination, vital signs, 12-lead , and laboratory tests be normal or slightly abnormal but not according to investigator's judgement.
  • Women of who are not exclusively in same-sex relationships and males with partners of child-bearing potential must agree to use adequate from signing the informed consent until 12 weeks after completion of the follow-up visit.
  • Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • A history of or current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
  • History of or evidence of tuberculosis.
  • History of recurrent or chronic infections.
  • Subjects with a history of meningococcal infection, or subjects who are exposed to Neisseria meningitidis.
  • History of asplenia or splenectomy.
  • History of abnormalities in complement or hereditary complement deficiency.
  • Received an agent within 30 days or 5-half-lives (whichever is longer) before the first dose of the study drug or being in other clinical study.
  • History or clinical evidence of drug abuse within 12 months before screening or positive screen for drugs of abuse.
  • Used prescribed or over-the-counter medication within 14 days or 5 half-lives (whichever is longer) before the first dose of the study drug unless determined not by the Investigator.
  • Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    SGB-9768

    a single dose of SGB-9768 by subcutaneous (sc) injection

    Drug: SGB-9768

  • Placebo comparator
    Placebo

    placebo calculated volume to match active treatment by sc injection

    Other: Placebo

Interventions

  • SGB-9768 for sc injection

  • OtherPlacebo

    sterile normal saline (0.9% NaCl) for sc injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of SGB-9768

    Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: 169 days

Secondary outcomes

  1. Pharmacokinetics-Cmax

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: 48 hours

  2. Pharmacokinetics-Tmax

    Time at which the maximum plasma concentration (Cmax) occurs

    Time frame: 48 hours

  3. Pharmacokinetics-AUClast

    Area under the plasma concentration-time curve from dosing (time zero) to the time of the last measured concentration

    Time frame: 48 hours

  4. Pharmacokinetics-AUCinf

    Area Under the Plasma Concentration Versus Time Curve from Zero Extrapolated to Infinity (AUCinf)

    Time frame: 48 hours

  5. Pharmacokinetics-t1/2

    Terminal Elimination Half-Life (t1/2)

    Time frame: 48 hours

  6. Pharmacokinetics-CL/F

    Total Body Clearance

    Time frame: 48 hours

  7. Pharmacokinetics-Vz/F

    Volume of Distribution (Vz/F)

    Time frame: 48 hours

  8. Pharmacodynamics-C3

    Change From Baseline in Complement 3 (C3)

    Time frame: 169 days

  9. Pharmacodynamics-complement acitvity

    Change From Baseline in Complement Activity

    Time frame: 169 days

07

Study locations

1 site
  • Huashan hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in May 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 15, 2024
StartActual
Jul 18, 2024
Primary completionActual
May 7, 2026
CompletionActual
May 7, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06501573
Lead sponsor
Suzhou Sanegene Bio Inc.
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 18, 2024
Primary completion
May 7, 2026
Completion
May 7, 2026
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGB-9768

Start the discussion